A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)Alberto Chiappori, M. S. Berger, Johnetta Blakely et al.|Journal of Clinical Oncology|2009Cited by 11
Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).Alberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2010Cited by 3